Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer

2010998 citationsJournal Article

Authors

Panitumumab plus FOLFIRI significantly improved PFS and is well-tolerated as second-line treatment in patients with WT KRAS mCRC.

Good health and well-being

Published in: Journal of Clinical Oncology

Volume 28, Issue 31, pp. 4706-4713

Field-Weighted Citation Impact: 43.98